Bębenek Marek, Duś Danuta, Koźlak Joanna
1 Department of Surgical Oncology, Regional Comprehensive Cancer Center, Wroclaw, Poland.
Contemp Oncol (Pozn). 2013;17(2):120-2. doi: 10.5114/wo.2013.34612. Epub 2013 Apr 29.
Fas and its ligand (FasL) are known to play a crucial role in the genetically controlled mechanism of cell death, and their deregulation in cancer cells is involved in the immune escape of the tumor. The aim of this review is to analyze the current knowledge on the prognostic value of Fas/FasL in breast cancer patients. Both the results of other authors and our own experiences indicate that the lack of Fas ligand, and particularly Fas, is related to a significantly worse prognosis. It probably results from the resistance of Fas-deficient breast tumors to the mechanisms of apoptosis. On the other hand, some results suggest that the Fas/FasL-dependent mechanisms of tumor spread may be different for various target tissues. The expression of the Fas/Fas-ligand system has potential prognostic application in view of current knowledge, and consequently should be considered as an additional prognostic factor in breast cancer patients.
已知Fas及其配体（FasL）在细胞死亡的基因控制机制中发挥关键作用，它们在癌细胞中的失调与肿瘤的免疫逃逸有关。本综述的目的是分析目前关于Fas/FasL在乳腺癌患者中的预后价值的知识。其他作者的结果以及我们自己的经验均表明，Fas配体的缺失，尤其是Fas的缺失，与显著更差的预后相关。这可能是由于缺乏Fas的乳腺肿瘤对凋亡机制具有抗性。另一方面，一些结果表明，Fas/FasL依赖性的肿瘤扩散机制可能因不同的靶组织而有所不同。鉴于目前的知识，Fas/Fas配体系统的表达具有潜在的预后应用价值，因此应被视为乳腺癌患者的一个额外预后因素。
